ReviewJournal of Cancer2020
Recent advances of drug delivery nanocarriers in osteosarcoma treatment.
Review in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 131 citations in OpenAlex.
- Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.Drug delivery · 2026Article
- Precision nanomedicine for lung metastatic osteosarcoma: challenges, therapeutic strategies, and perspectives.Materials today. Bio · 2026Review
- Nanochelate-based BCc1 delivery and its impact on key regulatory pathways in BALB/c breast cancer: An analysis ofBiochemistry and biophysics reports · 2026Article
- Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer.Oncology research · 2026Review
- Targeting Osteosarcoma: The Dual Action of Halogenated Boroxine and Cerium Oxide Nanoparticles.International journal of molecular sciences · 2025Article
- Green Synthesis of Biochar-Supported Nanoscale Zero-Valent Iron Using Tea Polyphenol for Efficient Cadmium Immobilization in Soil.Nanomaterials (Basel, Switzerland) · 2025Article
- Multiscale metal-based nanocomposites for bone and joint disease therapies.Materials today. Bio · 2025Review
- Transforming bone cancer treatment: a comprehensive review of green-synthesized metal nanoparticles.Cancer cell international · 2025Review
- Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Design and Synthesis of Mycophenolic Acid Analogues for Osteosarcoma Cancer Treatment.ACS bio & med chem Au · 2025Article
- Biodistribution and Tumor Targeted Accumulation of Anti-CEA-loaded Iron Nanoparticles.Current pharmaceutical biotechnology · 2025Article
- Self-Penetrating Oligonucleotide Derivatives: Features of Self-Assembly and Interactions with Serum and Intracellular Proteins.Pharmaceutics · 2023Article
- Nano-Based Drug Delivery Systems: Potential Developments in the Therapy of Metastatic Osteosarcoma-A Narrative Review.Pharmaceutics · 2023Review
- Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.Orthopaedic surgery · 2023Review
- Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions.Pharmaceutics · 2023Review
- Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.Journal of nanobiotechnology · 2023Review
- Nanosized drug delivery strategies in osteosarcoma chemotherapy.APL bioengineering · 2023Review
- PLGA-based drug delivery systems in treating bone tumors.Frontiers in bioengineering and biotechnology · 2023Review
- Enhanced Therapeutic Effects of an Antitumor Agent on Subcutaneous Tumors in Mice by Photomechanical Wave-based Transvascular Drug Delivery.Journal of Cancer · 2023Article
- Anti-EGFR Targeted Multifunctional I-131 Radio-Nanotherapeutic for Treating Osteosarcoma: In Vitro 3D Tumor Spheroid Model.Nanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common primary malignant bone tumor mainly occurred in children and adolescence, and chemotherapy is limited for the side effects and development of drug resistance. Advances in nanotechnology and knowledge of cancer biology have led to significant improvements in developing tumor-targeted drug delivery nanocarriers, and some have even entered clinically application. Delivery of chemotherapeutic agents by functionalized smart nanocarriers could protect the drugs from rapid clearance, prolong the circulating time, and increase the drug concentration at tumor sites, thus enhancing the therapeutic efficacy and reducing side effects. Various drug delivery nanocarriers have been designed and tested for osteosarcoma treatment, but most of them are still at experimental stage, and more further studies are needed before clinical application. In this present review, we briefly describe the types of commonly used nanocarriers in osteosarcoma treatment, and discuss the strategies for osteosarcoma-targeted delivery and controlled release of drugs. The application of nanoparticles in the management of metastatic osteosarcoma is also briefly discussed. The purpose of this article is to present an overview of recent progress of nanoscale drug delivery platforms in osteosarcoma, and inspire new ideas to develop more effective therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.